Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice

Skye Bioscience ( (SKYE) ) has issued an announcement.

On March 17, 2026, Skye Bioscience disclosed that it received a deficiency notice from Nasdaq after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, putting its Nasdaq Global Market listing at risk. The notice does not immediately affect trading, but Skye has until September 14, 2026, to restore compliance, potentially through measures such as a reverse stock split, and could receive an additional 180-day grace period if it meets other listing standards, leaving investors facing uncertainty over the company’s ability to maintain its current listing tier.

The most recent analyst rating on (SKYE) stock is a Hold with a $0.69 price target. To see the full list of analyst forecasts on Skye Bioscience stock, see the SKYE Stock Forecast page.

Spark’s Take on SKYE Stock

According to Spark, TipRanks’ AI Analyst, SKYE is a Neutral.

The score is held down primarily by weak financial performance (no revenue, widening losses, accelerating cash burn, and a shrinking equity cushion) and bearish technical signals. Offsetting positives come from the earnings-call and recent events highlighting runway visibility and encouraging Phase 2a combination data, but these are not yet enough to outweigh the current financial and trend headwinds.

To see Spark’s full report on SKYE stock, click here.

More about Skye Bioscience

Skye Bioscience, Inc. is a biopharmaceutical company whose common stock trades on The Nasdaq Global Market under the ticker symbol SKYE. The company’s shares are subject to Nasdaq’s continued listing standards, including minimum bid-price requirements that must be maintained to preserve its exchange listing status.

Average Trading Volume: 672,531

Technical Sentiment Signal: Sell

Current Market Cap: $22.47M

Learn more about SKYE stock on TipRanks’ Stock Analysis page.